Pharmacodynamics of peginterferon alfa‐2a and peginterferon alfa‐2b in interferon‐naïve patients with chronic hepatitis C: a randomized, controlled study

Summary Background  Peginterferon alfa-2a and alfa-2b, the two commercially available pegylated interferons, have different pharmacokinetic properties that produce differing abilities to suppress replication of the hepatitis C virus. Aim  To compare the pharmacodynamics of peginterferon alfa-2a and peginterferon alfa-2b in interferon-naive patients with chronic hepatitis C. Methods  Patients were randomized to receive peginterferon alfa-2a, 180 μg (n = 10) or peginterferon alfa-2b 1.0 μg/kg (n = 12) once weekly. The enzymatic activity of 2′5′-oligoadenylate synthetase and levels of neopterin and β2-microglobulin were measured at baseline and at 24, 48, 120 and 168 h. Results  Oligoadenylate synthetase activity and serum neopterin and β2-microglobulin concentrations did not differ significantly between the two patient groups at any time point, nor was there a significant correlation between the serum area under the concentration-time curve of either peginterferon and the area under the concentration-time curve for 2′,5′-oligoadenylate synthetase, neopterin and β2-microglobulin. The area under the concentration-time curves calculated for these three markers did not correlate with body mass index stratified at <25 and ≥25 kg/m2 for either peginterferon. Conclusions  Despite pharmacokinetic differences between peginterferon alfa-2a and peginterferon alfa-2b, the pharmacodynamic profiles of the two formulations appear to be comparable.